B-Raf specific antibody responses in melanoma patients.
BACKGROUND
Mutations of the BRAF gene are the most common genetic alteration in melanoma. Moreover, BRAF mutations are already present in benign nevi. Being overexpressed and mutated, B-Raf is a potential target for the immune system and as this mutation seems to be an early event, a humoral immune response against this antigen might serve as a diagnostic tool for detection of high risk patients.


METHODS
372 sera of 148 stage IV melanoma patients and 119 sera of non-melanoma patients were screened for B-Raf, B-Raf V599E and C-Raf specific antibodies by an ELISA assay. Sera were screened for specific total Ig and for IgG. Serum titers were compared with a two tailed Mann-Whitney U test. Sera with titers of 1:300 or higher were termed positive and groups were compared with a two tailed Fisher's exact test.


RESULTS
B-Raf specific antibodies recognizing both B-Raf and B-Raf V599E were detected in 8.9% of the sera of melanoma patients and in 2,5% of the control group. Raf specific IgG was detected in some patients at very low levels. B-Raf specific antibody responses did not correlate with clinical parameters but in some cases, B-Raf antibodies emerged during disease progression.


CONCLUSIONS
These findings imply that B-Raf is immunogenic in melanoma patients and that it might serve as a potential target for immunotherapy. However, B-Raf specific antibodies emerge at rather late stages of melanoma progression and are present only with a low frequency indicating that spontaneous B-Raf specific antibodies are not an early marker for melanoma, but rather may serve as a therapeutic target.
Fensterle
Joachim
J
Institut für Medizinische Strahlenkunde und Zellforschung (MSZ), University Clinics of Würzburg, Versbacher Str. 5, 97078 Würzburg, Germany. joachim.fensterle@mail.uni-wuerzburg.de
Becker
Jürgen C
JC
Potapenko
Tamara
T
Heimbach
Veronika
V
Vetter
Claudia S
CS
Bröcker
Eva B
EB
Rapp
Ulf R
UR
D000912:Antibodies, Neoplasm / Q000097:blood* / Q000276:immunology; D000918:Antibody Specificity; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008545:Melanoma / Q000276:immunology*; D048493:Proto-Oncogene Proteins B-raf / Q000276:immunology*; D012878:Skin Neoplasms / Q000097:blood / Q000276:immunology*
D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf